125 related articles for article (PubMed ID: 37816388)
1. Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous Thromboembolism.
Hussaini P; Larsen TL; Ghanima W; Dahm AEA
Thromb Haemost; 2024 Apr; 124(4):351-362. PubMed ID: 37816388
[TBL] [Abstract][Full Text] [Related]
2. Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up.
Larsen TL; Garresori H; Brekke J; Enden T; Frøen H; Jacobsen EM; Quist-Paulsen P; Porojnicu AC; Ree AH; Torfoss D; Osvik Velle E; Skuterud Wik H; Ghanima W; Sandset PM; Dahm AEA
J Thromb Haemost; 2022 May; 20(5):1166-1181. PubMed ID: 35114046
[TBL] [Abstract][Full Text] [Related]
3. Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism.
Hannevik TL; Brekke J; Enden T; Frøen H; Garresori H; Jacobsen EM; Paulsen PQ; Porojnicu AC; Ree AH; Torfoss D; Velle EO; Wik HS; Ghanima W; Sandset PM; Dahm AEA
Thromb Res; 2020 Dec; 196():238-244. PubMed ID: 32919178
[TBL] [Abstract][Full Text] [Related]
4. Oral apixaban for the treatment of acute venous thromboembolism.
Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI;
N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982
[TBL] [Abstract][Full Text] [Related]
5. Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism.
Houghton DE; Vlazny DT; Casanegra AI; Brunton N; Froehling DA; Meverden RA; Hodge DO; Peterson LG; McBane RD; Wysokinski WE
Mayo Clin Proc; 2021 Nov; 96(11):2793-2805. PubMed ID: 34425962
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
Rollins BM; Silva MA; Donovan JL; Kanaan AO
Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
[TBL] [Abstract][Full Text] [Related]
7. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
[TBL] [Abstract][Full Text] [Related]
8. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
[TBL] [Abstract][Full Text] [Related]
9. Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism.
Bott-Kitslaar DM; McBane RD; Casanegra AI; Houghton DE; Froehling DA; Vlazny DT; Ashrani AA; Hodge DO; Vargas ER; Bartlett MA; Saadiq RA; Daniels PR; Shields RC; Lenz CJ; Lang TR; Wysokinski WE
Mayo Clin Proc; 2019 Jul; 94(7):1242-1252. PubMed ID: 30737059
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Alotaibi G; Alsaleh K; Wu C; Mcmurtry MS
Int Angiol; 2014 Aug; 33(4):301-8. PubMed ID: 25056161
[TBL] [Abstract][Full Text] [Related]
11. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial.
Guntupalli SR; Brennecke A; Behbakht K; Tayebnejad A; Breed CA; Babayan LM; Cheng G; Ramzan AA; Wheeler LJ; Corr BR; Lefkowits C; Sheeder J; Matsuo K; Flink D
JAMA Netw Open; 2020 Jun; 3(6):e207410. PubMed ID: 32589230
[TBL] [Abstract][Full Text] [Related]
13. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
14. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
[TBL] [Abstract][Full Text] [Related]
15. Role of anticoagulants in therapy and prevention of recurrent venous thromboembolism in patients with cancer: a meta-analysis of randomized trials with apixaban.
Mareev VY; Mareev YV
Kardiologiia; 2022 Mar; 62(3):4-15. PubMed ID: 35414354
[TBL] [Abstract][Full Text] [Related]
16. Comparison of effectiveness and safety for low versus full dose of apixaban during extended phase oral anticoagulation in patients with venous thromboembolism.
DeRemer CE; Dietrich EA; Kang HR; Huang PL; Lo-Ciganic WH; Park H
J Intern Med; 2022 Jun; 291(6):877-885. PubMed ID: 35192737
[TBL] [Abstract][Full Text] [Related]
17. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity.
Crouch A; Ng TH; Kelley D; Knight T; Edwin S; ; Giuliano C
Pharmacotherapy; 2022 Feb; 42(2):119-133. PubMed ID: 34904263
[TBL] [Abstract][Full Text] [Related]
18. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials.
Loffredo L; Violi F; Perri L
Int J Cardiol; 2016 Jun; 212():255-8. PubMed ID: 27057930
[TBL] [Abstract][Full Text] [Related]
19. Apixaban: A Review in Venous Thromboembolism.
Greig SL; Garnock-Jones KP
Drugs; 2016 Oct; 76(15):1493-1504. PubMed ID: 27653758
[TBL] [Abstract][Full Text] [Related]
20. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism.
Verso M; Munoz A; Bauersachs R; Huisman MV; Mandalà M; Vescovo G; Becattini C; Agnelli G
Eur J Cancer; 2021 May; 148():371-381. PubMed ID: 33780665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
